Publication Date:
1987-06-05
Description:
The bcl-2 and c-myc proto-oncogenes are brought into juxtaposition with the immunoglobulin heavy chain locus in particular B-cell lymphomas, resulting in high levels of constitutive accumulation of their messenger RNAs. Precisely how the products of the bcl-2 and c-myc genes contribute to tumorigenesis is unknown, but observations that c-myc expression is rapidly induced in nonneoplastic lymphocytes upon stimulation of proliferation raise the possibility that this proto-oncogene is involved in the control of normal cellular growth. In addition to c-myc, the bcl-2 proto-oncogene also was expressed in normal human B and T lymphocytes after stimulation with appropriate mitogens. Comparison of the regulation of the expression of these proto-oncogenes demonstrated marked differences and provided evidence that, in contrast to c-myc, levels of bcl-2 messenger RNA are regulated primarily through transcriptional mechanisms.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Reed, J C -- Tsujimoto, Y -- Alpers, J D -- Croce, C M -- Nowell, P C -- CA-42232/CA/NCI NIH HHS/ -- New York, N.Y. -- Science. 1987 Jun 5;236(4806):1295-9.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/3495884" target="_blank"〉PubMed〈/a〉
Keywords:
Blood Proteins/biosynthesis/drug effects
;
Cycloheximide/pharmacology
;
Gene Expression Regulation/*drug effects
;
Humans
;
Interleukin-2/pharmacology
;
Kinetics
;
Lymphocyte Activation/*drug effects
;
Phytohemagglutinins/pharmacology
;
Proto-Oncogenes/*drug effects
;
RNA, Messenger/blood/drug effects
;
Transcription, Genetic/drug effects
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
